The EAHAD Gene Therapy Working Group was formed in 2019.
The working group will strive to be at the forefront of providing critical information to physicians and patients about gene therapy in terms of practicability and safety.
Its goals are:
– To investigate gene therapy safety and its outcome parameters.
– To provide updates on recent developments in terms of alanine aminotransferase (ALT) results and safety outcomes.
– To collect data on the different gene therapy trials, tests, and adverse events.
– To inform patients and medical professionals.
The members of the working group are:
|Prof. Dr Wolfgang Miesbach|
|Haematologist||Goethe University Hospital||Germany|
|Dr Pratima Chowdary||Haematologist||London Royal Free Hospital||United Kingdom|
|Dr Michiel Coppens||Haematologist||Amsterdam UMC||The Netherlands|
|Dr Dan Hart||Haematologist||London Royal Free Hospital||United Kingdom|
|Dr Robert Klamroth||Haematologist||Vivantes Klinikum im Friedrichshain||Germany|
|Prof. Michael Makris||Haematologist||University of Sheffield||United Kingdom|
|Declan Noone||President||European Haemophilia Consortium||Belgium|
|Prof. Flora Peyvandi||Haematologist||University of Milan||Italy|
|Dr Víctor Jiménez Yuste||Haematologist||La Paz University Hospital||Spain|
The EAHAD Gene Therapy Working Group is grateful for the funding it receives in support of its various activities from the following industry partners:
Delivery of AAV-based gene therapy through haemophilia centres—A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC
Selection of EAHAD 2021 Gene Therapy highlights (available on the ISTH GT website)
Gene Therapy Key Components of Clinical Care Session (available on the ISTH GT website)